Pancreas, Phase II-III
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Beverly Drucker, MD, PhD
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Katelyn Scott
- Kayla Martello
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Michael Cecchini, MD
- Osarugue Otasowie
- Pamela L. Kunz, MD
- Rebecca Vanasse-Passas, MD
- Robert Legare, MD
- Sarah Carlson
- Stacey Stein, MD
- Teresa White
- Vanna Dest
- Victor Chang, MD
- Wajih Kidwai, MD, FACP
- Last Updated05/03/2024
- Study HIC#2000034279